Menu

Waning Protection from Vaccination Explains Rise in Mumps Cases

A study finds that the vaccine’s effects wear off as a person ages, suggesting a need for booster shots.

Mar 22, 2018
Catherine Offord

US AIR FORCE, MATTHEW LOTZThe number of mumps cases has been increasing across the United States, a phenomenon that some researchers have suggested is due to evolution of the mumps virus to escape vaccination. But a more likely explanation is that vaccine-based protection against mumps wanes over a person’s lifetime, according to researchers at Harvard University. The findings, published yesterday (March 21) in Science, indicate a potential role for booster vaccines in maintaining protection throughout adulthood.

“Our results strongly support that the answer is waning vaccine-induced immunity, not a new vaccine-escape strain,” study coauthor Yonatan Grad, an infectious disease specialist at the Harvard T.H. Chan School of Public Health, tells The Philadelphia Inquirer.

Before the introduction of the mumps vaccine in 1967 in the U.S., more than 90 percent of children and adolescents came down with the infection. Although that percentage plummeted in the 1970s, the number of mumps infections saw spikes in the 1980s and 1990s, and again in 2006, particularly among young adults.

To understand the fluctuations, the Harvard researchers studied epidemiological data from a handful of studies carried out in Europe and in the U.S. between 1967 and 2008. The pair found that immunity from vaccination seems to last an average of 27 years, with a range of 16 years to 51 years, and that without further vaccination, people eventually return to being vulnerable to the virus.

“The pattern we observed is a lot more consistent with what we would expect from a waning vaccine,” study coauthor Joseph Lewnard of Harvard’s T.H. Chan School of Public Health, tells CNN. He adds that this is “a reassuring message,” in that it could be relatively easily addressed with one or several booster vaccines at age 18 or older.

Vaccine expert Stanley Plotkin of VaxConsult in West Chester, Pennsylvania, tells Science that the findings don’t rule out a role for viral evolution altogether. “From my point of view, both factors are important,” he says.

Nevertheless, he adds that he is in favor of booster vaccines for young adults. “Something needs to be done,” he says. “The simplest thing, the thing we can do today, is to propose a third dose of MMR on entry to university colleges, which would help to prevent outbreaks from occurring.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

Cell culture made easy with new 24-channel pipetting heads for VIAFLO 96/384
Cell culture made easy with new 24-channel pipetting heads for VIAFLO 96/384
INTEGRA has responded to customers’ requests and developed two new 24-channel pipetting heads, extending the capabilities of its popular VIAFLO 96/384.
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.